Global Genetic Engineering Market
Global Genetic Engineering Market

Genetic Engineering Comprehensive Study by Type (Artificial Selection, Cloning, Gene Splicing, Others), Application (Medical Industry, Recombinant Proteins, Recombinant Antibodies, Forensic Science, Others), End User (Research Institutes, Academic Institutes, Pharmaceutical Industries, Others.) Players and Region - Global Market Outlook to 2025

Genetic Engineering Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Jan 2019 Edition 204 Pages 193 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
Due to increasing occurrences of distinctive diseases across the globe, the demand for customized or personalized medicines manufactured with the help of genetic engineering is significantly up surged in past few years. The enhancements and technological innovations in genetic engineering will create numerous opportunities in the emerging economies that will ultimately help in improving the demand for genetic engineering. With the help of genetic engineering it is possible to directly manipulate an organism's genes using biotechnology.This growth is primarily driven by Increasing Adoption in Pharmaceutical Industry and Robust Government Funding on Genetic Engineering.

Globally, a noticeable market trend is evident Increasing Adoption in Agriculture Industry . The Life Sciences Tools & Services sector in the North America region has been increasing at a strong rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Horizon Discovery Group Plc. (United Kingdom), Transposagen Biopharmaceuticals Inc. (United States), New England Biolabs (United States), Genscript Biotech Corporation (United States), Lonza Group Ltd. (Switzerland) Inc. (United States), Origene Technologies, Inc. (United States), Integrated DNA Technologies, Inc. (United States) and CRISPR Therapeutics (Switzerland) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
On December 14, 2018, Merck, which is also known as MSD outside North America is a privately held Antelliq Group has announced that the companies have signed a definitive agreement under which Merck will acquire Antelliq with a cash payment of approximately 2.1 billion euros to acquire all outstanding shares of Antelliq and will assume Antelliq’s debt of 1.15 billion euros, which it intends to repay shortly after the closing of the acquisition.

Regulatory Insights:
According to Genetically Modified Seeds’ Resolution 46/2004 on Genetically Modified Plant Organisms, It is obligatory to complete an additional registration in a specific National Registry of Operators of Genetically Modified Plant Organisms by all those who conduct experiments, import, export, produce, reproduce, or carry out any activity related to genetically modified plants that have not been approved for commercialization in Argentina.

Market Drivers
  • Increasing Adoption in Pharmaceutical Industry
  • Robust Government Funding on Genetic Engineering

Market Trend
  • Increasing Adoption in Agriculture Industry
  • Robust Technological Advancements

Restraints
  • Less Favorable Amount of Diversity Created by Genetic Engineering
  • Unintended Negative Consequences

Opportunities
Rising Prevalence of Distinctive Diseases and Increasing Usage in Developing Economies
Challenges
Copyrighted Process in Number of Regions including United States

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Artificial Selection
  • Cloning
  • Gene Splicing
  • Others
By Application
  • Medical Industry
  • Recombinant Proteins
  • Recombinant Antibodies
  • Forensic Science
  • Others
By End User
  • Research Institutes
  • Academic Institutes
  • Pharmaceutical Industries
  • Others.

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Adoption in Pharmaceutical Industry
      • 3.2.2. Robust Government Funding on Genetic Engineering
    • 3.3. Market Challenges
      • 3.3.1. Copyrighted Process in Number of Regions including United States
    • 3.4. Market Trends
      • 3.4.1. Increasing Adoption in Agriculture Industry
      • 3.4.2. Robust Technological Advancements
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Genetic Engineering, by Type, Application, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Genetic Engineering (Value)
      • 5.2.1. Global Genetic Engineering by: Type (Value)
        • 5.2.1.1. Artificial Selection
        • 5.2.1.2. Cloning
        • 5.2.1.3. Gene Splicing
        • 5.2.1.4. Others
      • 5.2.2. Global Genetic Engineering by: Application (Value)
        • 5.2.2.1. Medical Industry
        • 5.2.2.2. Recombinant Proteins
        • 5.2.2.3. Recombinant Antibodies
        • 5.2.2.4. Forensic Science
        • 5.2.2.5. Others
      • 5.2.3. Global Genetic Engineering by: End User (Value)
        • 5.2.3.1. Research Institutes
        • 5.2.3.2. Academic Institutes
        • 5.2.3.3. Pharmaceutical Industries
        • 5.2.3.4. Others.
      • 5.2.4. Global Genetic Engineering Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Genetic Engineering: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck KGaA (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Horizon Discovery Group Plc. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Transposagen Biopharmaceuticals Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. New England Biolabs (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Genscript Biotech Corporation (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lonza Group Ltd. (Switzerland) Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Origene Technologies, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Integrated DNA Technologies, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CRISPR Therapeutics (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Genetic Engineering Sale, by Type, Application, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Genetic Engineering (Value)
      • 7.2.1. Global Genetic Engineering by: Type (Value)
        • 7.2.1.1. Artificial Selection
        • 7.2.1.2. Cloning
        • 7.2.1.3. Gene Splicing
        • 7.2.1.4. Others
      • 7.2.2. Global Genetic Engineering by: Application (Value)
        • 7.2.2.1. Medical Industry
        • 7.2.2.2. Recombinant Proteins
        • 7.2.2.3. Recombinant Antibodies
        • 7.2.2.4. Forensic Science
        • 7.2.2.5. Others
      • 7.2.3. Global Genetic Engineering by: End User (Value)
        • 7.2.3.1. Research Institutes
        • 7.2.3.2. Academic Institutes
        • 7.2.3.3. Pharmaceutical Industries
        • 7.2.3.4. Others.
      • 7.2.4. Global Genetic Engineering Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Genetic Engineering: by Type(USD Billion)
  • Table 2. Genetic Engineering Artificial Selection , by Region USD Billion (2013-2018)
  • Table 3. Genetic Engineering Cloning , by Region USD Billion (2013-2018)
  • Table 4. Genetic Engineering Gene Splicing , by Region USD Billion (2013-2018)
  • Table 5. Genetic Engineering Others , by Region USD Billion (2013-2018)
  • Table 6. Genetic Engineering: by Application(USD Billion)
  • Table 7. Genetic Engineering Medical Industry , by Region USD Billion (2013-2018)
  • Table 8. Genetic Engineering Recombinant Proteins , by Region USD Billion (2013-2018)
  • Table 9. Genetic Engineering Recombinant Antibodies , by Region USD Billion (2013-2018)
  • Table 10. Genetic Engineering Forensic Science , by Region USD Billion (2013-2018)
  • Table 11. Genetic Engineering Others , by Region USD Billion (2013-2018)
  • Table 12. Genetic Engineering: by End User(USD Billion)
  • Table 13. Genetic Engineering Research Institutes , by Region USD Billion (2013-2018)
  • Table 14. Genetic Engineering Academic Institutes , by Region USD Billion (2013-2018)
  • Table 15. Genetic Engineering Pharmaceutical Industries , by Region USD Billion (2013-2018)
  • Table 16. Genetic Engineering Others. , by Region USD Billion (2013-2018)
  • Table 17. South America Genetic Engineering, by Country USD Billion (2013-2018)
  • Table 18. South America Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 19. South America Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 20. South America Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 21. Brazil Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 22. Brazil Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 23. Brazil Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 24. Argentina Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 25. Argentina Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 26. Argentina Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 27. Rest of South America Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 28. Rest of South America Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 29. Rest of South America Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 30. Asia Pacific Genetic Engineering, by Country USD Billion (2013-2018)
  • Table 31. Asia Pacific Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 32. Asia Pacific Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 33. Asia Pacific Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 34. China Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 35. China Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 36. China Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 37. Japan Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 38. Japan Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 39. Japan Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 40. India Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 41. India Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 42. India Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 43. South Korea Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 44. South Korea Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 45. South Korea Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 46. Taiwan Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 47. Taiwan Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 48. Taiwan Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 49. Australia Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 50. Australia Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 51. Australia Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 52. Rest of Asia-Pacific Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 53. Rest of Asia-Pacific Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 54. Rest of Asia-Pacific Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 55. Europe Genetic Engineering, by Country USD Billion (2013-2018)
  • Table 56. Europe Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 57. Europe Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 58. Europe Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 59. Germany Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 60. Germany Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 61. Germany Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 62. France Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 63. France Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 64. France Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 65. Italy Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 66. Italy Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 67. Italy Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 68. United Kingdom Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 69. United Kingdom Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 70. United Kingdom Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 71. Netherlands Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 72. Netherlands Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 73. Netherlands Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 74. Rest of Europe Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 75. Rest of Europe Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 76. Rest of Europe Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 77. MEA Genetic Engineering, by Country USD Billion (2013-2018)
  • Table 78. MEA Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 79. MEA Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 80. MEA Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 81. Middle East Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 82. Middle East Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 83. Middle East Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 84. Africa Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 85. Africa Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 86. Africa Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 87. North America Genetic Engineering, by Country USD Billion (2013-2018)
  • Table 88. North America Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 89. North America Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 90. North America Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 91. United States Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 92. United States Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 93. United States Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 94. Canada Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 95. Canada Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 96. Canada Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 97. Mexico Genetic Engineering, by Type USD Billion (2013-2018)
  • Table 98. Mexico Genetic Engineering, by Application USD Billion (2013-2018)
  • Table 99. Mexico Genetic Engineering, by End User USD Billion (2013-2018)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Genetic Engineering: by Type(USD Billion)
  • Table 111. Genetic Engineering Artificial Selection , by Region USD Billion (2019-2024)
  • Table 112. Genetic Engineering Cloning , by Region USD Billion (2019-2024)
  • Table 113. Genetic Engineering Gene Splicing , by Region USD Billion (2019-2024)
  • Table 114. Genetic Engineering Others , by Region USD Billion (2019-2024)
  • Table 115. Genetic Engineering: by Application(USD Billion)
  • Table 116. Genetic Engineering Medical Industry , by Region USD Billion (2019-2024)
  • Table 117. Genetic Engineering Recombinant Proteins , by Region USD Billion (2019-2024)
  • Table 118. Genetic Engineering Recombinant Antibodies , by Region USD Billion (2019-2024)
  • Table 119. Genetic Engineering Forensic Science , by Region USD Billion (2019-2024)
  • Table 120. Genetic Engineering Others , by Region USD Billion (2019-2024)
  • Table 121. Genetic Engineering: by End User(USD Billion)
  • Table 122. Genetic Engineering Research Institutes , by Region USD Billion (2019-2024)
  • Table 123. Genetic Engineering Academic Institutes , by Region USD Billion (2019-2024)
  • Table 124. Genetic Engineering Pharmaceutical Industries , by Region USD Billion (2019-2024)
  • Table 125. Genetic Engineering Others. , by Region USD Billion (2019-2024)
  • Table 126. South America Genetic Engineering, by Country USD Billion (2019-2024)
  • Table 127. South America Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 128. South America Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 129. South America Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 130. Brazil Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 131. Brazil Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 132. Brazil Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 133. Argentina Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 134. Argentina Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 135. Argentina Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 136. Rest of South America Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 137. Rest of South America Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 138. Rest of South America Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 139. Asia Pacific Genetic Engineering, by Country USD Billion (2019-2024)
  • Table 140. Asia Pacific Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 141. Asia Pacific Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 142. Asia Pacific Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 143. China Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 144. China Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 145. China Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 146. Japan Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 147. Japan Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 148. Japan Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 149. India Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 150. India Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 151. India Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 152. South Korea Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 153. South Korea Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 154. South Korea Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 155. Taiwan Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 156. Taiwan Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 157. Taiwan Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 158. Australia Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 159. Australia Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 160. Australia Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 161. Rest of Asia-Pacific Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 162. Rest of Asia-Pacific Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 163. Rest of Asia-Pacific Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 164. Europe Genetic Engineering, by Country USD Billion (2019-2024)
  • Table 165. Europe Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 166. Europe Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 167. Europe Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 168. Germany Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 169. Germany Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 170. Germany Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 171. France Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 172. France Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 173. France Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 174. Italy Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 175. Italy Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 176. Italy Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 177. United Kingdom Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 178. United Kingdom Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 179. United Kingdom Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 180. Netherlands Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 181. Netherlands Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 182. Netherlands Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 183. Rest of Europe Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 184. Rest of Europe Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 185. Rest of Europe Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 186. MEA Genetic Engineering, by Country USD Billion (2019-2024)
  • Table 187. MEA Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 188. MEA Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 189. MEA Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 190. Middle East Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 191. Middle East Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 192. Middle East Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 193. Africa Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 194. Africa Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 195. Africa Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 196. North America Genetic Engineering, by Country USD Billion (2019-2024)
  • Table 197. North America Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 198. North America Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 199. North America Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 200. United States Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 201. United States Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 202. United States Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 203. Canada Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 204. Canada Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 205. Canada Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 206. Mexico Genetic Engineering, by Type USD Billion (2019-2024)
  • Table 207. Mexico Genetic Engineering, by Application USD Billion (2019-2024)
  • Table 208. Mexico Genetic Engineering, by End User USD Billion (2019-2024)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Genetic Engineering: by Type USD Billion (2013-2018)
  • Figure 5. Global Genetic Engineering: by Application USD Billion (2013-2018)
  • Figure 6. Global Genetic Engineering: by End User USD Billion (2013-2018)
  • Figure 7. South America Genetic Engineering Share (%), by Country
  • Figure 8. Asia Pacific Genetic Engineering Share (%), by Country
  • Figure 9. Europe Genetic Engineering Share (%), by Country
  • Figure 10. MEA Genetic Engineering Share (%), by Country
  • Figure 11. North America Genetic Engineering Share (%), by Country
  • Figure 12. Global Genetic Engineering share by Players 2018 (%)
  • Figure 13. Global Genetic Engineering share by Players (Top 3) 2018(%)
  • Figure 14. Global Genetic Engineering share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2018
  • Figure 18. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck KGaA (Germany) Revenue: by Geography 2018
  • Figure 20. Horizon Discovery Group Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 21. Horizon Discovery Group Plc. (United Kingdom) Revenue: by Geography 2018
  • Figure 22. Transposagen Biopharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Transposagen Biopharmaceuticals Inc. (United States) Revenue: by Geography 2018
  • Figure 24. New England Biolabs (United States) Revenue, Net Income and Gross profit
  • Figure 25. New England Biolabs (United States) Revenue: by Geography 2018
  • Figure 26. Genscript Biotech Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 27. Genscript Biotech Corporation (United States) Revenue: by Geography 2018
  • Figure 28. Lonza Group Ltd. (Switzerland) Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Lonza Group Ltd. (Switzerland) Inc. (United States) Revenue: by Geography 2018
  • Figure 30. Origene Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Origene Technologies, Inc. (United States) Revenue: by Geography 2018
  • Figure 32. Integrated DNA Technologies, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Integrated DNA Technologies, Inc. (United States) Revenue: by Geography 2018
  • Figure 34. CRISPR Therapeutics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. CRISPR Therapeutics (Switzerland) Revenue: by Geography 2018
  • Figure 36. Global Genetic Engineering: by Type USD Billion (2013-2018)
  • Figure 37. Global Genetic Engineering: by Application USD Billion (2013-2018)
  • Figure 38. Global Genetic Engineering: by End User USD Billion (2013-2018)
  • Figure 39. South America Genetic Engineering Share (%), by Country
  • Figure 40. Asia Pacific Genetic Engineering Share (%), by Country
  • Figure 41. Europe Genetic Engineering Share (%), by Country
  • Figure 42. MEA Genetic Engineering Share (%), by Country
  • Figure 43. North America Genetic Engineering Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Thermo Fisher Scientific Inc. (United States)
  • Merck KGaA (Germany)
  • Horizon Discovery Group Plc. (United Kingdom)
  • Transposagen Biopharmaceuticals Inc. (United States)
  • New England Biolabs (United States)
  • Genscript Biotech Corporation (United States)
  • Lonza Group Ltd. (Switzerland) Inc. (United States)
  • Origene Technologies, Inc. (United States)
  • Integrated DNA Technologies, Inc. (United States)
  • CRISPR Therapeutics (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation